NZ702479A - Compositions and methods for treating bacterial infections using ceftaroline - Google Patents

Compositions and methods for treating bacterial infections using ceftaroline

Info

Publication number
NZ702479A
NZ702479A NZ702479A NZ70247910A NZ702479A NZ 702479 A NZ702479 A NZ 702479A NZ 702479 A NZ702479 A NZ 702479A NZ 70247910 A NZ70247910 A NZ 70247910A NZ 702479 A NZ702479 A NZ 702479A
Authority
NZ
New Zealand
Prior art keywords
ceftaroline
compositions
infection
methods
bacterial infections
Prior art date
Application number
NZ702479A
Inventor
George Talbot
Dirk Thye
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to NZ717866A priority Critical patent/NZ717866A/en
Publication of NZ702479A publication Critical patent/NZ702479A/en

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed are pharmaceutical compositions comprising ceftaroline fosamil for treatment of a bacterial infection, wherein the composition comprises from about 200 mg to about 800 mg of ceftaroline fosamil, about 0.6 to about 0.7 equivalents (w/w) of the pH stabilizer L-arginine as compared to ceftaroline fosamil, less than 2% of the L-arginine adduct of formula I or II, and the composition provides a mean AUC for ceftaroline in patients with a creatinine clearance from about 50 to about 80 ml/min of about 1.2 times greater than the mean AUC for ceftaroline in patients with a creatinine clearance of greater than about 80 ml/min. Also disclosed is the use of the pharmaceutical composition in the preparation of a medicament for the treatment of a bacterial infection, particularly where the infection is a complicated skin and skin structure infection or community-acquired bacterial pneumonia.
NZ702479A 2009-09-21 2010-09-21 Compositions and methods for treating bacterial infections using ceftaroline NZ702479A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ717866A NZ717866A (en) 2009-09-21 2010-09-21 Compositions and methods for treating bacterial infections using ceftaroline

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24412009P 2009-09-21 2009-09-21
US29490110P 2010-01-14 2010-01-14
NZ59893510 2010-09-21

Publications (1)

Publication Number Publication Date
NZ702479A true NZ702479A (en) 2016-06-24

Family

ID=56132537

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ717866A NZ717866A (en) 2009-09-21 2010-09-21 Compositions and methods for treating bacterial infections using ceftaroline
NZ702479A NZ702479A (en) 2009-09-21 2010-09-21 Compositions and methods for treating bacterial infections using ceftaroline

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ717866A NZ717866A (en) 2009-09-21 2010-09-21 Compositions and methods for treating bacterial infections using ceftaroline

Country Status (1)

Country Link
NZ (2) NZ717866A (en)

Also Published As

Publication number Publication date
NZ717866A (en) 2017-09-29

Similar Documents

Publication Publication Date Title
PH12015501678A1 (en) Inhibitors of influenza viruses replication
MY188960A (en) Cyclic boronic acid ester derivatives and therapeutic uses thereof
BR112015014458A2 (en) mannose derivatives for the treatment of bacterial infections
MX2013006846A (en) Inhibitors of influenza viruses replication.
MX2010002392A (en) Improved brimonidine compositions for treating erythema.
IN2014CN00562A (en)
GEP20156366B (en) Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2012083122A8 (en) Inhibitors of influenza viruses replication
WO2008054454A3 (en) Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
MX2011009709A (en) Compounds for treating inflammation and pain.
WO2009123776A3 (en) Antiviral drugs for treatment of arenavirus infection
TW200639159A (en) Treatment of pain
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
EA201390626A1 (en) DERIVATIVES OF HYDROXAMIC ACID AND APPLICATION OF INDICATED DERIVATIVES IN THE TREATMENT OF BACTERIAL INFECTIONS
WO2009043987A9 (en) Antibiotic compositions containing essential oils, prophylaxis and treatment of nosocomial diseases
CN113164420A (en) Therapeutic compositions
MX2010009624A (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1.
NZ596628A (en) Ketolide compounds having antimicrobial activity
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
MX2012014918A (en) Compounds and methods for the treatment or prevention of flavivirus infections.
MX2009006325A (en) 2-quinolinone and 2-quinoxalinone- derivatives and their use as antibacterial agents.
MX2013002208A (en) Sulfonylpiperazine derivatives that interact with glucokinase regulatory protein for the treatment of diabetes.
RU2015112121A (en) MI-RNA AND THEIR APPLICATION IN METHODS AND COMPOSITIONS FOR TREATMENT AND / OR PREVENTION OF EYE CONDITIONS
MY160005A (en) 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
NZ702479A (en) Compositions and methods for treating bacterial infections using ceftaroline

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 21 SEP 2017 BY AJ PARK

Effective date: 20161220

ASS Change of ownership

Owner name: PFIZER ANTI-INFECTIVES AB, SE

Effective date: 20170309

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 SEP 2018 BY THOMSON REUTERS

Effective date: 20170819

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 SEP 2019 BY THOMSON REUTERS

Effective date: 20180816

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 SEP 2020 BY THOMSON REUTERS

Effective date: 20190817

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 SEP 2021 BY THOMSON REUTERS

Effective date: 20200820

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 SEP 2022 BY THOMSON REUTERS

Effective date: 20210803

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 SEP 2023 BY THOMSON REUTERS

Effective date: 20220801

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 SEP 2024 BY THOMSON REUTERS

Effective date: 20230802